Mitsubishi UFJ Trust & Banking Corp Raises Stock Holdings in Illumina, Inc. $ILMN

Mitsubishi UFJ Trust & Banking Corp increased its position in Illumina, Inc. (NASDAQ:ILMN) by 18.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 229,408 shares of the life sciences company’s stock after purchasing an additional 36,178 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Illumina were worth $30,089,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Board of the Pension Protection Fund purchased a new stake in Illumina in the fourth quarter worth $26,000. Creative Capital Management Investments LLC grew its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in Illumina in the fourth quarter worth $26,000. Quent Capital LLC purchased a new stake in Illumina in the third quarter worth $29,000. Finally, Quarry LP purchased a new stake in Illumina in the third quarter worth $32,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ILMN shares. Robert W. Baird set a $137.00 target price on Illumina in a research note on Friday, February 6th. Stifel Nicolaus increased their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. UBS Group reissued a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Guggenheim increased their target price on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus price target of $129.69.

Illumina Trading Down 5.2%

Shares of NASDAQ:ILMN opened at $120.37 on Thursday. The company has a market cap of $18.29 billion, a P/E ratio of 22.09, a PEG ratio of 2.46 and a beta of 1.49. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. Illumina, Inc. has a 1 year low of $73.86 and a 1 year high of $155.53. The stock’s fifty day moving average price is $125.55 and its 200-day moving average price is $126.43.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.12 earnings per share for the current year.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.90% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.